IFNA1 and systemic lupus erythematosus: An increased IFN signature has been identified in many autoimmune diseases, including SLE, rheumatic arthritis (RA), systemic sclerosis (SSc) and dermatomyositis (DM), and its utility as a biomarker to predict disease severity or to assess disease activity is readily studied (9–16).